See more : Lex Nimble Solutions Limited (LEX.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Citius Pharmaceuticals, Inc. (CTXR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Citius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- High Tide Inc. (HITI) Income Statement Analysis – Financial Results
- Virgin Orbit Holdings, Inc. (VORB) Income Statement Analysis – Financial Results
- Cesar SA (ALCES.PA) Income Statement Analysis – Financial Results
- Regent Ventures Ltd. (RGVNF) Income Statement Analysis – Financial Results
- Alpha Tau Medical Ltd. (DRTSW) Income Statement Analysis – Financial Results
Citius Pharmaceuticals, Inc. (CTXR)
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -194.32K | -179.68K | -164.87K | -152.36K | -893.00 | -1.75K | -2.63K | -1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.82M | 17.66M | 12.24M | 8.81M | 8.60M | 6.56M | 2.94M | 2.93M | 1.80M | 437.97K | 492.14K | 705.81 | 0.00 |
| General & Administrative | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 310.30 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.31K | 0.00 |
| SG&A | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 19.62K | 25.64K |
| Other Expenses | 0.00 | 1.45M | 59.92K | 110.21K | 715.98K | 1.27M | 732.15K | 732.15K | 486.27K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Cost & Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Interest Income | 1.18M | 251.40K | 261.83K | 68.07K | 52.66K | 0.00 | 806.00 | 806.00 | 3.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 251.40K | 10.84K | 15.67K | 16.44K | 15.84K | 850.79K | 8.99K | 7.50K | 0.00 | 3.25K | 2.39K | 0.00 |
| Depreciation & Amortization | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 3.07K | 1.15M | 1.18M | 1.02K | 704.00 |
| EBITDA | -36.73M | -32.88M | -22.88M | -17.38M | -15.54M | -13.79M | -9.98M | -7.45M | -3.23M | 0.00 | 0.00 | -19.62K | -24.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.73M | -33.32M | -23.53M | -17.71M | -15.60M | -13.79M | -9.99M | -7.45M | -3.23M | -1.15M | -28.12K | -19.62K | -25.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.77M | 251.40K | 477.46K | 162.60K | 36.22K | 1.25M | -398.64K | -846.41K | 327.66K | 171.82K | 0.00 | -2.39K | -704.00 |
| Income Before Tax | -31.97M | -33.06M | -23.05M | -17.55M | -15.56M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 576.00K | 576.00K | 70.76K | 125.88K | 16.44K | 1.28M | 850.79K | 8.99K | 4.43K | -119.15K | -1.18M | -1.02K | 0.00 |
| Net Income | -32.54M | -33.64M | -23.13M | -17.67M | -15.58M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| Weighted Avg Shares Out | 146.13M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
| Weighted Avg Shares Out (Dil) | 151.29M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
CRANFORD, N.J. , Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person...
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
CRANFORD, N.J. , Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a...
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
CRANFORD, N.J. , Nov. 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today closed its previously announced registered direct offering...
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
CRANFORD, N.J. , Nov. 15, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% Objective Response Rate (ORR) 33% Clinical Benefit Rate (CBR) with a median Progression...
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present...
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in...
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
Granted FDA approval of LYMPHIR™ for the treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024, under ticker CTOR Achieved primary and secondary endpoints...
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on...
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on...
Source: https://incomestatements.info
Category: Stock Reports